Health & Fitness
Health and Fitness
Health and Fitness
Tue, July 10, 2012
Mon, July 9, 2012
Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference -- SAN DIEGO, July 9, 2012 /PRNewswire/ --
Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
SAN DIEGO, July 9, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: [ OREX ]) today announced that management will present a company overview at the JMP Securities Healthcare Conference in New York. The presentation is scheduled for Thursday, July 12th at 3:00 p.m. EDT. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at [ www.orexigen.com ]. A replay will be available for 14 days after the event.
About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at [ www.orexigen.com ].
Orexigen Contact: | Media Contact: |
McDavid Stilwell | Denise Powell |
VP, Corporate Communications and Business Development | WCG |
(858) 875-8629 | (510) 703-9491 |
SOURCE Orexigen Therapeutics, Inc.
[ Back to top ]
RELATED LINKS
[ http://www.orexigen.com ]
